RT Journal Article
SR Electronic
T1 D06 Platelet Bdnf In Huntington’s Disease: Evidence From A Preliminary Study
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP A33
OP A34
DO 10.1136/jnnp-2014-309032.98
VO 85
IS Suppl 1
A1 Mazzucchi, S
A1 Unti, E
A1 Kiferle, L
A1 Palego, L
A1 Giannaccini, G
A1 Lucacchini, A
A1 Bonuccelli, U
A1 Ceravolo, R
YR 2014
UL http://jnnp.bmj.com/content/85/Suppl_1/A33.2.abstract
AB Background Brain Derived Neurotrophic Factor (BDNF) is a neurotrophin implicated in the pathogenesis of neurodegenerative diseases and mood disorders; highly expressed in central nervous system, it can be detected in peripheral tissues such as blood, mainly stored in platelets. Wild type huntingtin (HTT) is believed to activate BDNF transcription and transport, mutated HTT is responsible for reduction of BDNF levels by inhibiting both processes. Several studies investigated BDNF in HD patients demostrating lower values in brain, blood and plasma with respect to controls; however results were not always confirmed and this lack of concordance could be due to extreme variability of sampling collection and laboratory techniques. Aims To evaluate BDNF levels in HD and possible correlations with psychiatric and motor scales by using platelet dosage. Methods 12 patients with symptomatic HD (S&F stage II) and 10 controls, matched for age and educational level were investigated by means of neuropsychological tests (MoCa, MMSE, FAB), psychiatric scales (BDI, PBA) and motor evaluation (UHDRS). Blood samples were collected to investigate BDNF platelet levels determined by ELISA. Results HD patients showed statistically significant lower performances at MoCa (p < 0.01) and FAB (p < 0.01). Platelet BDNF was higher in patients (2950.5 ± 749.1 pg/ml) with respect to controls (2481.6 ± 1063.8 pg/ml) but the difference was not statistically significant. Further analysis demonstrated a direct correlation between disease duration and BDNF platelet levels (p < 0.05). Conclusions Our finding of a lack of significant difference in platelet BDNF between HD and controls could suggest along with recent studies on human blood that peripheral levels of BDNF are not informative as HD biomarkers. However, the correlation between BDNF platelet levels and disease duration might indicate that the peripheral BDNF levels can fluctuate in different phases of the disease.